Cancer News and Research

Latest Cancer News and Research

BioMimetic Therapeutics reports net loss of $4.6 million for third quarter 2012

BioMimetic Therapeutics, Inc. today reported its corporate highlights and financial results as of and for the three and nine months ended September 30, 2012. For the three months ended September 30, 2012, the Company reported a net loss of $4.6 million, or $0.16 per diluted share, compared to a net loss of $7.1 million, or $0.25 per diluted share, for the same period in 2011.

6 Nov 2012

Dysregulation of CISTR-ACT causes brachydactyly type E

The patients have single short fingers (metacarpals) and toes (metatarsals) and can be restricted in growth due to a shortened skeleton. This hereditary disease is called brachydactyly type E (Greek for short fingers).

6 Nov 2012

Virttu launches REPLICATE- Open Innovation Forum

Virttu Biologics Limited, a UK biotechnology company with expertise in the field of oncolytic viruses, has announced the launch of the Virttu REPLICATE- Open Innovation Forum.

6 Nov 2012

Inhibition of NOX4 enzyme plays an important role in liver fibrosis

Researchers at the Bellvitge Biomedical Research Institute (IDIBELL) have led a study published in PLoS One showing that the inhibition of a family member of NADPH oxidase enzyme, NOX4, plays an important role in liver fibrosis.

5 Nov 2012

Tengion receives U.S. patent allowance titled ‘Isolated Renal Cells and Uses Thereof’

Tengion, Inc., a leader in regenerative medicine, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 12/617,721, titled "Isolated Renal Cells and Uses Thereof."

5 Nov 2012

No link between daily multivitamin use and reduction of major cardiovascular events in men

In a randomized study that included nearly 15,000 male physicians who were middle-aged or older, daily multivitamin use for more than 10 years of treatment and follow-up did not result in a reduction of major cardiovascular events, heart attack, stroke, or death from cardiovascular disease, according to a study appearing in November 7 issue of JAMA, a theme issue on cardiovascular disease.

5 Nov 2012

Endo, Bioniche decide to end second Urocidin Phase III trial on non-muscle-invasive bladder cancer

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced that a second Phase III clinical trial with Urocidin in non-muscle-invasive bladder cancer is being discontinued.

5 Nov 2012

Surgical features determine survival in radical prostatectomy patients

The impact of adjuvant radiotherapy on cancer-specific mortality and overall mortality rates in patients who have undergone radical prostatectomy depends on the cumulative number of certain pathologic features found during surgery, report researchers.

5 Nov 2012

Cervical cancer risk remains high after CIN treatment

Women who undergo treatment for screening-detected cervical intraepithelial neoplasia are more than four times more likely to develop cervical cancer than women with normal smear tests, research suggests.

5 Nov 2012

Sapacitabine tolerated, efficacious in elderly leukemia patients

The nucleoside analog sapacitabine appears to be “active and tolerable” in elderly patients with acute myeloid leukemia, say authors of a phase II study reported in the Lancet Oncology.

5 Nov 2012

AcelRx commences dosing in ARX-04 sufentanil NanoTab Phase 2 study for acute and breakthrough pain

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it has dosed the first subjects in a Phase 2, placebo-controlled, dose-finding study of its ARX-04 sufentanil NanoTab product candidate.

5 Nov 2012

PsiOxus receives UK government grant to initiate ColoAd1 Phase I/II trial for ovarian cancer

PsiOxus Therapeutics, Ltd., a development stage biotechnology company, today announced the award of a £1.7 million ($2.7 million) grant from the UK government-backed Biomedical Catalyst to initiate a Phase I/II clinical trial to assess the use of ColoAd1 in the treatment of platinum-resistant, recurrent ovarian cancer.

5 Nov 2012

Vitamin D deficiency: an interview with Kellie Bilinski

We know that vitamin D is important in keeping bones strong. In the last 30-40 years it has also been realized that vitamin D has a lot of other roles in the body. Vitamin D essentially has a role in any cell in the body that has a vitamin D receptor.

5 Nov 2012

New insight on ability of certain PAH-derived lesions to evade DNA repair machinery

A person doesn't have to go far to find a polycyclic aromatic hydrocarbon (PAH). These carcinogen precursors are inhaled through automobiles exhaust during the morning commute, are present in a drag of cigarette smoke, and are part of any barbequed meal.

4 Nov 2012

First study to measure minute changes in breast tumor connective tissue fibers

Using advanced microscopes equipped with tissue-penetrating laser light, cancer imaging experts at Johns Hopkins have developed a promising, new way to accurately analyze the distinctive patterns of ultra-thin collagen fibers in breast tumor tissue samples and to help tell if the cancer has spread.

3 Nov 2012

Isis Pharmaceuticals to receive $1.25M from Pfizer for continued advancement of EXC 001

Isis Pharmaceuticals, Inc. announced today that it will receive a $1.25 million contingent payment from Pfizer Inc. triggered by Pfizer's decision to advance EXC 001 into a Phase 2 study.

3 Nov 2012

Bristol-Myers Squibb welcomes decision by NICE to recommend Yervoy for advanced melanoma

Today, Bristol-Myers Squibb is pleased to welcome the decision by The National Institute for Health and Clinical Excellence (NICE) to recommend Yervoy (ipilimumab) for the treatment of previously-treated advanced (unresectable or metastatic) melanoma within the Final Appraisal Determination (FAD).

3 Nov 2012

Sausalito Shine a Light on Lung Cancer Vigil to be held on Nov. 13 in the U.S.

This event will shine a light on one of the United States' most deadly and overlooked epidemics. Lung cancer kills approximately 160,000 Americans annually - more than breast, prostate and colon cancers combined - and has the worst survival rate of all cancers.

3 Nov 2012

Weill Cornell researchers awarded Grand Challenges Explorations grants

Weill Cornell Medical College announced today that it is a Grand Challenges Explorations winner, an initiative funded by the Bill & Melinda Gates Foundation.

3 Nov 2012

Data from four Phase 2 trials of AMG 145 to be presented at AHA Scientific Sessions 2012

Amgen will present data from four Phase 2 trials of AMG 145, an investigational fully human monoclonal antibody directed against PCSK9, a protein that reduces the liver's ability to remove low density lipoprotein cholesterol, or "bad" cholesterol from the blood, at the upcoming American Heart Association Scientific Sessions 2012.

3 Nov 2012

Cancer News and Research

Latest Cancer News and Research

BioMimetic Therapeutics reports net loss of $4.6 million for third quarter 2012

Dysregulation of CISTR-ACT causes brachydactyly type E

Virttu launches REPLICATE- Open Innovation Forum

Inhibition of NOX4 enzyme plays an important role in liver fibrosis

Tengion receives U.S. patent allowance titled ‘Isolated Renal Cells and Uses Thereof’

No link between daily multivitamin use and reduction of major cardiovascular events in men

Endo, Bioniche decide to end second Urocidin Phase III trial on non-muscle-invasive bladder cancer

Surgical features determine survival in radical prostatectomy patients

Cervical cancer risk remains high after CIN treatment

Sapacitabine tolerated, efficacious in elderly leukemia patients

AcelRx commences dosing in ARX-04 sufentanil NanoTab Phase 2 study for acute and breakthrough pain

PsiOxus receives UK government grant to initiate ColoAd1 Phase I/II trial for ovarian cancer

Vitamin D deficiency: an interview with Kellie Bilinski

New insight on ability of certain PAH-derived lesions to evade DNA repair machinery

First study to measure minute changes in breast tumor connective tissue fibers

Isis Pharmaceuticals to receive $1.25M from Pfizer for continued advancement of EXC 001

Bristol-Myers Squibb welcomes decision by NICE to recommend Yervoy for advanced melanoma

Sausalito Shine a Light on Lung Cancer Vigil to be held on Nov. 13 in the U.S.

Weill Cornell researchers awarded Grand Challenges Explorations grants

Data from four Phase 2 trials of AMG 145 to be presented at AHA Scientific Sessions 2012

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

A new method to measure intracellular water in biological systems

Obesity, GLP-1s, and metabolic care

Automation in cell-based workflows

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

A new method to measure intracellular water in biological systems

Obesity, GLP-1s, and metabolic care

Automation in cell-based workflows

Newsletters you may be interested in